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Amyotrophic lateral sclerosis (ALS) is a rapidly disabling and fatal neurodegenerative dis-
ease. Due to insufficient disease-modifying treatments, there is an unmet and urgent need
for elucidating disease mechanisms that occur early and represent common triggers in
both familial and sporadic ALS. Emerging evidence suggests that impaired DNA damage
response contributes to age-related somatic accumulation of genomic instability and can
trigger or accelerate ALS pathological manifestations. In this review, we summarize and
discuss recent studies indicating a direct link between DNA damage response and ALS.
Further mechanistic understanding of the role genomic instability is playing in ALS disease
pathophysiology will be critical for discovering new therapeutic avenues.
Amyotrophic lateral sclerosis (ALS) is a lethal degenerative motor neuron disease with a median sur-
vival of 2–4 years after diagnosis [1] and no available effective treatment [2]. Caused by loss of motor
neurons in the motor cortex, brain stem and spinal cord, the worldwide annual incidence of ALS is ap-
proximately 1 per 50,000 live births and is expected to exponentially increase in the next 20 years [3]. Since
it leads to severe disability with high fatality rate, there is an extensive socioeconomic burden alongside
the unmet medical need [1,4,5]. Most likely, as for most neurodegenerative diseases, one of the reasons for
the slow progression in the development of novel therapies in ALS is the fact that the underlying neurode-
generation may start decades before clinical diagnosis [6–10]. Thus, a better understanding of the disease
mechanisms that appear early and represent common triggers in both familial (fALS) and sporadic (sALS)
forms of ALS is required as to inform on early diagnostic/prognostic markers and therapies.
Although ALS is a mainly sporadic disease (90–95% of patients) [11], attention has been focused on
the 5–10% of patients that have fALS where a gene-disease association can be made (Figure 1). Currently
around 30 genes associated with fALS have been identified [12–16] and while a common molecular mech-
anism remains uncertain, recent evidence suggests that accumulation of genomic instability (GIN) – via
impaired DNA damage recognition or defective DNA repair – is one of the hallmarks of ALS (Figure 2
and Table 1) [17].
Without excluding the importance and relevance of other molecular mechanisms that have been ex-
tensively covered by others [18–21], in this review we will examine the evidence revealing a role for the
DNA damage response (DDR) in ALS, by discussing some of the particular genes, proteins and cellular
processes implicated at the intersection of the DDR and ALS.
Sources of genomic instability and connection to ALS
DDR is starting to be recognized as a unifying mechanism in neurodegenerative disorders [22]. DNA
damage can arise from both endogenous and exogenous sources and if not repaired will lead to the ac-
cumulation of GIN and ensuing pathologies [23]. To enable normal neuronal functions and survival, the
DDR encompasses complex mechanisms that recognize DNA damage and signal for DNA damage repair
[22,24]. Increasing evidence indicates that mature neurons are highly dependent on accurate DDR and
that DNA damage accumulation accelerates in the normal human brain particularly after 40 years of age
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Figure 1. ALS patient stratification
Although some genetic heterogeneity is observed across the world, literature suggests these are the approximate proportions of














































Figure 2. Molecular hallmarks of ALS
Current evidence suggests several underlying etiological factors in ALS. Genomic instability, caused by defective DNA damage
signalling or DNA repair, toxic DNA repair, impaired clearance of endogenous genotoxic stressors (i.e. ROS), or due to imbalanced
chromatin structure states, could be a unifying pathophysiological characteristic of the disease.
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Table 1 DDR associated mutations in ALS
Gene DDR link
TDP-43 TAR DNA-binding protein 43; ALS-linked mutations [145]; impairs DDR in ALS [34]
FUS/TLS Fused in sarcoma; ALS-linked mutation [79,146]; impairs DDR in ALS [147]
HNRNP Heterogeneous nuclear ribonucleoprotein; modifies TDP43 [148,149]; associated with DDR [150]; hnRNP L recruits
53BP1 and BRCA1 in cancer [151]; hnRNP F,H, and K are related to ALS [152] and p53 recruitment [153]
HNRNPA1 ALS linked mutations [154]; telomere protection and telomerase activation [155]; regulated by TDP43 [156]
HNRNPA2/B1 ALS linked mutations [154]
SARM1 Sterile alpha and TIR motif containing 1; ALS linked mutations [157]; SARM1 deletion suppresses TDP43-linked ALS
[158]
PFN1 Profilin-1; mutated PFN1 aggregates and shifts TDP43 from nuclei to cytoplasm in ALS [159]
UBQLN2 Ubiquilin-2; ALS-linked mutations [160]; interacts with TDP43 [161]
CCNF Cyclin F; ALS-linked mutations [162]; increases ubiquitinated TDP43 [162]
ERBB4 Erb-B2 Receptor Tyrosine Kinase 4; interacts with TDP43 [163]; regulates p53-dependent DDR [164]; interacts with
KAP1 for DDR [165]; activates p53 and p21 [166]
SIGMAR1 Sigma nonopioid intracellular receptor 1; interacts with TDP43 [167]
GLE1 RNA export mediator; ALS-linked mutations [168]; interacts with TDP43 [169]; GLE1 deletion increases phosphorylated
H2AX, decreases BRCA1 and FANCD2 and increases ATR resulting in delayed DDR [170]
SOD1 Superoxide dismutase; ALS-linked mutations [33]; protects DNA from oxidative stress damage in ALS [171]
DAO D-amino acid oxidase; ROS production [172]
KIAA1563/ALS2 Alsin; ALS-linked mutations [154]; increases ROS in ALS [173]; regulates autophagy [174]
C9ORF72 Induces DNA damage in ALS [175]
SETX Senataxin; encodes a DNA/RNA helicase protein involved in DDR and RNA production in ALS4 (Juvenile ALS) [176,177]
ATXN2 Ataxin-2; ALS-linked mutations [178]; R-loop suppressor [65]; affects R-loop in ALS [179]
VCP Valosin-containing protein; ALS-linked mutations [180]; facilitates 53BP1 recruitment for DSB repair [17,181]; causes
p62 accumulation in ALS [182]
NEK1 NIMA-Related Kinase 1; mutation induces DNA damage in ALS and impairs ATM-mediated DDR [183]
C21ORF2 NEK1 interactor; involved in HR repair [48,157]
MATR3 Matrin-3; activated by ATM and involved in the early stage of the DSB response [184]
SQSTM1 /p62 Sequestosome-1; inhibits nuclear RNF168; an E3 ligase essential for histone H2A ubiquitination and DDR [185]
TBK1 TANK-binding kinase 1; ALS-linked mutations [157]; an inducer of type-1 interferons; major role in autophagy and
mitophagy [186]; cGAS/Sting/TBK1/IRF3 regulates p21 maintaining chromosomal stability [138]
ELP3 Elongator complex protein 3; ALS-linked mutations [154]; binds to PCNA; linked to DNA replication and repair [187]
TIA1 T-cell intracellular antigen 1; affects DDR; binds to p53 mRNA and controls p53 expression [188]; promotes phase
separation and alters SG dynamics in ALS [15]
[25]. With ageing, there is thus an even greater requirement for DDR, and failure to deal with GIN accumulation will
eventually lead to increased neuronal loss. Paradoxically, the DDR is known to change and deteriorate with age [26].
GIN arises from the buildup of lesions, such as base modifications, abasic sites, single- or double-stranded breaks
(SSBs; DSBs) [27,28]. DSBs are particularly deleterious and, if left unrepaired, are detrimental to cell survival. DSBs
are repaired by homologous recombination (HR) and non-homologous end joining (NHEJ). Carried out exclusively
in cells that are in S- or G2-phase of the cell cycle, HR is the preferential DSB repair pathway as it is a relatively
error-free process. Because under physiological conditions neurons are outside of the replicative cell cycle in the
quiescent G0-phase, even though error-prone, NHEJ is the primary repair pathway for DSBs. That being said, recent
evidence suggests that in addition to classical NHEJ, neurons could employ transcription-coupled repair mechanisms
utilizing mRNA as a template for homology directed repair [29].
Since mature neurons are post-mitotic non-replicating cells that are difficult to replace [30,31], unsanctioned neu-
ronal loss will lead to neurodegeneration. Concomitantly, ageing also brings other imbalances that can accelerate such
DDR-related processes [32].
In ALS, the endogenous sources contributing to deleterious accumulation of GIN are from both impaired removal
of reactive metabolic genotoxins (i.e. reactive oxygen species; ROS) that can overwhelm DDR [33] and from the
incapability to recognize or repair DNA damage [34,35]. Although in this review, we are focusing on endogenous
sources of DNA damage, one must keep in mind the geographical heterogeneity of ALS that cannot be explained
by genetic risk factors alone [12,36]. Thus, future research should consider environmental genotoxic influences that
might also play a role in both sALS and fALS.
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Figure 3. SOD1 plays a dual role in DDR
SOD1 nuclear translocation is ATM/CDS1-dependent. Once SOD1 enters the nucleus, it activates transcription (TR) of many genes
that are involved in DDR or ROS defence. SOD1 regulates SPY1 expression, which activates CDK2, a G1- to S-phases check point.
Other cell cycle regulation (CCR) gene mutations (e.g. NEK1, C21ORF2 and CCNF) are implicated in defective DDR, suggesting a
role for atypical cell cycle re-entry (ACCR) in ALS. Mutated genes identified in ALS (red), homologous recombination (HR; green),
atypical cell cycle checkpoint (AACR; purple) and ROS regulation (yellow). Dotted arrows are proposed, yet not completely proven,
interactions.
SOD1 and DNA damage in ALS
Superoxide dismutase 1 (SOD1) is a free radical scavenging enzyme that in the cytoplasm catalyzes the conversion of
superoxide anions formed during mitochondrial respiration into hydrogen peroxide [37] and protects motor neurons
– which are particularly prone to the toxic effects of mutant and dysfunctional SOD1 – against oxidative damage and
neurodegeneration [33]. In both sALS and fALS, SOD1-induced neuronal toxicity occurs through gain-of-function
mutations (Figure 1) [33,38] that lead to accumulation of injuries produced from the unscheduled free radical attack
on pyrimidine and purine bases [39,40]. Secondarily, in both sALS and fALS, SOD1 can be secreted as monomers into
the extracellular space leading to cell death [41]. Unexpectedly, recent data show that independent from its catalytic
function, SOD1 performs additional roles in the nucleus. In response to elevated ROS, in an ataxia-telangiectasia mu-
tated (ATM; a core DDR gene [42]) dependent manner, CDP-diacylglycerol synthase 1 (CDS1) kinase phosphorylates
SOD1 at S60 and S99 promoting rapid SOD1 translocation to the nucleus where it regulates the expression of a large set
of genes involved in oxidative stress defence and DDR [43]. Furthermore, nuclear SOD1 increases SpeedyA1 (SPY1)
expression promoting cell survival and inhibiting damage-induced apoptosis. In ALS, pathologic SOD1–G93A can-
not translocate to the nucleus and exercise its protective role via SPY1 regulation [44]. SPY1 is a nuclear protein
that controls the transition between G1- and S-phases of the cell cycle via checkpoint-dependent kinase 2 (CDK2)
activation [45]. In neurons, re-entry into cell cycle (CCR) is partly controlled by ATM, is atypical, and leads to neu-
ronal death [30,46,47]. The observation that SOD1 can influence such decisions will require further investigation
especially since other fALS genes, such as NEK1, C21ORF2 and CCNF are also involved in cell cycle progression
[48–51], suggesting CCR should be considered in ALS pathology.
Thus, SOD1 protection against DNA damage accumulation is bi-modal, with the first tier of defence being exe-
cuted in the cytoplasm through ROS scavenging, and the second in the nucleus where it controls the expression of
DDR-related genes (Figure 3).
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Figure 4. Role for TDP43 and FUS in maintaining genome stability in ALS
Pathway choice is directed by the balance between TDP43 and FUS interaction at break sites. Simplified model for the role of TDP43
(a) and FUS (b) in DDR. Mutated genes identified in ALS (red), atypical cell cycle checkpoint (AACR; purple), non-homologous
end-joining (NHEJ; blue), homologous recombination (HR; green) and base excision repair (BER; chartreuse). Dotted arrows are
proposed, yet not completely proven, interactions.
TDP43 mislocalization impairs DDR
Transactivation response DNA-binding protein 43 (TDP43) is a highly conserved nuclear protein that acts as tran-
scription and splicing regulator as well as scaffold for nuclear bodies [52]. While in normal conditions TDP43 is
primarily localized in the nucleus, in disease states it gets trapped in insoluble cytoplasmic inclusions (stress gran-
ules; SG; see Figure 4a) [53,54]. Although mutated TDP43 accounts for only approximately 4% of fALS cases (Figure
1), TDP43-SG accumulation is a pathology characteristic for ∼95% of all ALS and ∼50% of frontotemporal dementia
(FTD) cases [21,55–57], as well as a secondary pathology in other neurodegenerative diseases, including Alzheimer’s
[58], Parkinson’s [59] and Huntington’s diseases [60,61].
Pathologic TDP43 mislocalization activates the mitochondrial unfolded protein response [62], elevates ROS levels
and affects cytoplasmic-nuclear trafficking, eventually leading to increased neuronal stress and subsequent cell death
[63,64]. Associated with such stress, GIN accumulation was described in sALS and fALS patients as well as in model
organisms with orthologous TDP43 loss-of-function [34]. In addition, TDP43 cytoplasmic retention can be aggra-
vated by other factors such as ataxin 2 (ATXN2), itself associated with DDR processes [65], thereby further increasing
the risk of developing ALS [66]. Furthermore, TDP43 mislocalization and GIN accumulation maintain a vicious cy-
cle via casein kinase 1ε (CK1ε) that has been shown to promote cytoplasmic accumulation of TDP43 [67]. Together
with other CK1 isoforms, CK1ε is activated upon GIN build-up and controls several cellular processes linked to DNA
damage signalling and repair, including apoptosis and cell cycle checkpoint control (Figure 4a) [68].
Although initially the connection between TDP43 dysfunction and the accumulation of GIN in ALS was thought
to be a secondary feature, recent evidence shows that neuronal TDP43 plays an important direct role in DDR by con-
trolling the nuclear recruitment of the XRCC4-DNA ligase 4 (LIG4) complex, critical for DSB repair via NHEJ [63].
In ALS/FTD, TDP43 nuclear exclusion incapacitates the transport of XRCC4/LIG4 leading to abortive NHEJ with
consequent accumulation of toxic DSBs. The involvement of DSB repair in ALS/FTD is further substantiated by the
observation that other proteins mutated in fALS such as valosin-containing protein (VCP)/p97 and sequestosome
1(SQSTM1)/p62 are linked to NHEJ [69,70]. VCP has been shown to directly interact with the canonical NHEJ pro-
teins Ku70/80 [69] as well as with ring finger proteins (RNF) 8/168 [71] to balance DNA repair pathway choice and
promote cell survival. This process is done in close correlation with SQSTM1/p62 that via interactions with ATM,
RAD50 and RNF168 also regulates the choice between HR and NHEJ in favour of the latter [70]. The TDP43/XRCC4
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direct connection is somewhat unexpected as replicating cells have less of a requirement for TDP43 in NHEJ (Figure
4a). This should prompt a more detailed analysis of these pathways in neurons where the relationship between dif-
ferent DDR components might be rewired. Further studies will be required to look, for example, at the interplay be-
tween TDP43 and other NHEJ proteins, such as PAXX and XRCC4-like factor (XLF) [72] or the SHIELDIN complex
[73]. Additionally, given its RNA-binding capabilities, TDP43 has been implicated in impeding DNA:RNA hybrids
(R-loops) formation [17,74]. This places TDP43 squarely in the middle of both DSB repair and the transcriptional
stress that neurons endure.
FUS-mediated solid-to-liquid phase transition promotes DDR
in ALS
Fused in sarcoma (FUS) is a nuclear ribonucleoprotein involved in a variety of cellular functions including transcrip-
tion, protein translation and RNA splicing and transport [75,76]. Initially studied for its roles in cancer [77,78], it was
later discovered that around 5% of fALS and 1% of sALS cases are associated with FUS mutations (Figure 1) [79].
Following oxidative damage, in a poly(ADP-ribose) polymerase (PARP1)-dependent manner, FUS facilitates the
recruitment of XRCC1/LIG3 to SSBs and enhances LIG3 ligation activity thus promoting base excision repair (BER;
Figure 4b) [80–83]. These interactions are, at least, partly based on the ability of FUS to rapidly traffic to the nu-
cleus, as mutations in the nuclear localization sequence induce FUS aggregation, genomic instability, and consecutive
neurodegeneration [84]. Additionally, in ATM and DNA-PKcs-dependent manner, FUS is involved in DSB repair
by directly controlling the recruitment of histone deacetylases 1 (HDAC1) to chromatin [35]. The involvement of
FUS in HDAC1 recruitment and activation is bimodal. Firstly, following DSB induction, FUS recruitment of HDAC1
promotes deacetylation and activation of NHEJ [85]. Secondly, in a PARP-dependent manner, FUS interacts with
RNA-binding motif protein 45 (RBM45) and prevents excessive recruitment of HDAC1 [86].
These data build a model in which FUS controls the choice between SSB repair and DSB repair pathways in healthy
neurons. Further research will be required to specifically understand the connection between FUS and TDP43 in DDR
as well as the requirement of HR versus microhomology mediated end-joining (alternative NHEJ; MMEJ). In some
patients, ALS is evidenced to manifest on the basis of oligogenic rather than monogenic alterations, with summative
effects from several DDR pathologies [87], as indicated in Figure 4.
C9ORF72 repeat expansion and impaired DDR in ALS
Nucleotide repeat expansion (NRE) disorders encompass more than 20 human genetic diseases, most of which affect
the nervous system, that arise from an expansion of a particularly unstable tandem of 3–12 DNA bases [88,89]. The
deleterious effects of these NREs depend on the location of the repeat within the affected gene, its sequence, as well
as the size of the repeat. C9ORF72 ALS/FTD is caused by the expansion of a hexanucleotide GGGGCC (G4C2) track
in the first intron of the C9ORF72 gene [90].
G4C2–NREs are pathogenic through several non-exclusive mechanisms that can all influence the accumulation
of DNA damage lesions and affect their repair (Figure 5A). Initially, transcription over G4C2 tracks is problematic
and will lead to accumulation of R-loops [91,92] and accumulation of toxic DNA secondary structures, hairpins and
G-quadruplexes, which require DDR to be resolved [93,94]. Intriguingly, mutations in the R-loop processing factors
senataxin (SETX) and HNRNPD also lead to fALS [95,96]. Subsequently or in parallel, transcripts containing repeats
can form RNA repeat expansion (RRE) foci that will bind and sequester various RNA-binding proteins such as TDP43,
FUS, nucleophosmin (NPM1) or AP endonuclease (APE1), potentially altering their localization and DDR functions
[91,97–105]. Finally, the G4C2–NREs are non-AUG (RAN) translated into dipeptide repeats (DPR)-containing pro-
teins (poly-GR; -GP; -GA; -PR; -PA) that form inclusions throughout the brain of patients with ALS/FTD [106–109]
and can lead to endoplasmic reticulum (ER) stress, mitochondrial dysfunction with ROS accumulation [110] and
sequestration of DDR proteins [111,112]. Moreover, DPRs can accumulate at the nuclear membrane and the nuclear
pore complex (NPC) to promote nuclear membrane abnormalities (NMA), impaired nuclear-cytoplasmic transport
[113–115] and imbalanced chromatin states [116]. Furthermore, in a vicious feedback loop, the expanded G4C2 can
interfere with the transcription and translation of the C9ORF72 mRNA thus leading to decreased autophagy and
further accumulation of DPRs [117].
Consequence of these pathologic mechanisms, C9ORF72 ALS/FTD patients show increased GIN accumulation
both in the brain [118] and spinal cord [97] where presence of DDR markers can be detected. One of the clearest
evidences for a direct DDR deficiency in ALS comes from the observation that expressing RREs and/or DPRs re-
sults in elevated R-loop levels and DSBs build-up in rat neurons, human cells and C9ORF72 ALS patient spinal cord
tissues. This is as a result of the incapability of C9ORF72-ALS neurons to mount a suitable DDR signalling cascade
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Figure 5. DDR defects in ALS with C9orf72 mutations
G4C2–NREs in the first intron of the C9ORF72 gene increases RRE, which impairs DDR through binding to RNA-binding proteins.
Transcription over G4C2–NREs leads to R-loop formation and subsequent DNA damage accumulation. RAN translation produced
DPRs that can increase ROS, induce nuclear membrane alterations (NMA) and may potentially sequester DDR proteins. NMA
include structural and functional disturbances at the nuclear pore complexes (NPC) involving transport receptors. Abnormal nu-
cleo-cytoplasmic transport of both RNA and proteins at NPC has been suggested to be, either related to molecule sequestrations
by DPR and RRE or in parallel with other factors, a strong C9ORF72 disease modifier. G4C2–NREs also decreases C9ORF72
expression, which impairs autophagy and exacerbates DPRs accumulation. Mutated genes identified in ALS (red), homologous
recombination (HR; green) and autophagy (brown). Dotted arrows are proposed, yet not completely proven, interactions.
which occurs due to defective ATM-mediated signalling that arises as a consequence of SQSTM1/p62 accumulation
and impaired H2A ubiquitylation (Figure 5A). Most likely due to this ATM signalling problem, NHEJ seems to be
up-regulated to toxic levels that can be rescued in fly models via Ku (NHEJ), APEX1 (BER) or ERCC1 (interstrand
cross-link DNA repair) dysregulation [119]. Although more information is needed to understand where the NHEJ
or other DNA repair dependent toxicity is coming from, such observation would be in line with similar mechanisms
present in ATM deficient replicating cells [120].
Another important link between G4C2 expansion and DDR is the observation that DPR accumulation leads to
imbalanced chromatin states with impact on DNA repair [121]. Poly-PR, for example, specifically binds DNA at het-
erochromatin, evicts HP1α and causes abnormal histone H3 methylation leading to altered chromatin structure and
NMA [116]. In response to endogenous DNA damage, to activate DDR, HP1α is phosphorylated by ATM [122],
while H3K9me3 is required to activate the acetyltransferase activity of TIP60 [123]. Moreover, DPR accumulation at
the nuclear membrane can lead to nuclear membrane rupture with subsequent GIN [124,125] as well as bi-directional
transport defects at the NPC resulting in impaired shuttling of RNA and proteins. Such transport disturbances might
interfere with factors involved in DDR and DNA repair, further feeding a vicious circle of DNA damage with in-
sufficient repair [57,84,126]. These mechanisms might also influence the onset of age-related ALS, as perturbed
nucleo-cytoplasmic cargo delivery is itself a feature of the CNS ageing process [127]. Thus, because the NPC has
been shown to play important roles in DNA repair and the organization of genome architecture [128] while in re-
sponse to DNA damage chromatin undergoes dramatic genome-wide changes that are at the heart of DDR [129],
further scrutiny will be required to apprehend the relationship between nuclear DPR accumulation at specific nu-
clear structures (i.e. NPC), imbalanced chromatin states and their link to DDR in ALS.
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Neuroinflammation and DDR in ALS
It must be highlighted that neurons do not live in isolation, and neurodegeneration is associated with microglial
reactivity and activation of innate immune responses. Neuroinflammation is a common characteristic of ALS and
comprises the stimulation of microglia, astrocytes and inflammatory T cells [130]. Upon activation, these cells se-
crete proinflammatory cytokines, such as tumour necrosis factor α, interferon γ, and interleukin 1β [131,132]. Typ-
ically, the innate immune response is activated by the presence of foreign cytoplasmic DNA via activation of cyclic
GMP–AMP synthetase, (cGAS), and the cyclic dinucleotide receptor, stimulator of interferon genes (STING) [133].
Recently, more attention is being given to the link between accumulating GIN, the subsequent leakage of DNA in the
cytoplasm and the activation of the cGAS-STING cascade [134]. In this model, ALS-GIN accumulating neurons can
amass increasing amounts of single-stranded DNA (ssDNA) in the cytoplasm and promote neuroinflammation with
production of cytokines and subsequent neuronal death (Figure 5B). Interestingly, haploinsufficiency in the STING
activating kinase TANK-binding kinase (TBK1) [135] is associated with fALS and FTD [136,137] (Figure 5B). Within
this pathway, TBK1 is important for several functions, including maintenance of chromosomal stability [138]. A func-
tional cGAS/STING pathway is also known to be required for normal chromosomal segregation in cancer cells via a
p21-dependent mechanism modulating G2/M transition [138]. The putative genome surveillance role in post-mitotic
non-replicating cells is less clear.
Neuroinflammation with subsequent neurodegeneration can also result from a glia autonomous problem in deal-
ing with DDR. Mutant human TDP43 expressed specifically in Drosophila glial cells causes DNA damage, elevated
replication of retrotransposable elements (RTE) [139], and Gypsy endogenous retroviruses [140] and apoptosis in the
nearby neurons. During their replication, the expression of RTE cDNA can lead to genome instability and accumu-
lation of DSBs [141]. These studies highlight that TDP43 mutations in glial cells promote ALS progression, at least
partly through impaired DDR signalling. Among glia, aberrant astrocyte function has also been implicated in ALS
pathology which has been discussed extensively by others and merits further research [142–144]. Further studies will
be required to better understand the relationship between DDR and neuroinflammation in ALS/FTD.
Conclusion
ALS is one of the most common adult-onset neurodegenerative disorders. Currently, ALS is fatal and incurable with
patients expected to survive ∼2–4 years after diagnosis, revealing an urgent need for effective therapeutic strategies.
Proof of DNA damage accumulation and DNA repair deficiency in both ALS initiation and progression is amassing,
highlighting the fact that genomic instability is a hallmark of disease pathogenesis. Shedding light on the specific
DDR mechanisms at play has important therapeutic potential.
Summary
• Genomic instability is a hallmark of both sporadic and familial ALS with many ALS genes involved in
recognition or repair of DNA damage.
• Outside of the nucleus SOD1 works to impede ROS accumulation and in the nucleus to influence
DNA damage response via transcription regulation.
• TDP43 and FUS work mainly to balance the pathway choice between SSB repair and DSB repair.
• Expansion of a repeated G4C2 track in the C9ORF72 gene leads to impaired ATM signalling.
• Genomic instability may be a starting point for neuroinflammation in ALS.
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114 Jovičić, A., Mertens, J., Boeynaems, S., Bogaert, E., Chai, N., Yamada, S.B. et al. (2015) Modifiers of C9orf72 dipeptide repeat toxicity connect
nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18, 1226–1229, https://doi.org/10.1038/nn.4085
115 Zhang, C.-Z., Spektor, A., Cornils, H., Francis, J.M., Jackson, E.K., Liu, S. et al. (2015) Chromothripsis from DNA damage in micronuclei. Nature 522,
179–184, https://doi.org/10.1038/nature14493
116 Zhang, Y.-J., Guo, L., Gonzales, P.K., Gendron, T.F., Wu, Y., Jansen-West, K. et al. (2019) Heterochromatin anomalies and double-stranded RNA
accumulation underlie C9orf72 poly(PR) toxicity. Science 363, eaav2606, https://doi.org/10.1126/science.aav2606
117 Boivin, M., Pfister, V., Gaucherot, A., Ruffenach, F., Negroni, L., Sellier, C. et al. (2020) Reduced autophagy upon C9ORF72 loss synergizes with
dipeptide repeat protein toxicity in G4C2 repeat expansion disorders. EMBO J. 39, e100574, https://doi.org/10.15252/embj.2018100574
118 Walker, C., Herranz-Martin, S., Karyka, E., Liao, C., Lewis, K., Elsayed, W. et al. (2017) C9orf72 expansion disrupts ATM-mediated chromosomal break
repair. Nat. Neurosci. 20, 1225–1235, https://doi.org/10.1038/nn.4604
119 Lopez-Gonzalez, R., Yang, D., Pribadi, M., Kim, T.S., Krishnan, G., Choi, S.Y. et al. (2019) Partial inhibition of the overactivated Ku80-dependent DNA
repair pathway rescues neurodegeneration in C9ORF72 -ALS/FTD. Proc. Natl. Acad. Sci. 116, 9628–9633, https://doi.org/10.1073/pnas.1901313116
120 Balmus, G., Pilger, D., Coates, J., Demir, M., Sczaniecka-Clift, M., Barros, A.C. et al. (2019) ATM orchestrates the DNA-damage response to counter
toxic non-homologous end-joining at broken replication forks. Nat. Commun. 10, 87, https://doi.org/10.1038/s41467-018-07729-2
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